Filtered By:
Therapy: Immunotherapy

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 258 results found since Jan 2013.

Ru(II)-modified TiO < sub > 2 < /sub > nanoparticles for hypoxia-adaptive photo-immunotherapy of oral squamous cell carcinoma
Biomaterials. 2022 Aug 24;289:121757. doi: 10.1016/j.biomaterials.2022.121757. Online ahead of print.ABSTRACTThe alternations in the hypoxic and immune microenvironment are closely related to the therapeutic effect and prognosis of oral squamous cell carcinoma (OSCC). Herein, a new nanocomposite, TiO2@Ru@siRNA is constructed from a ruthenium-based photosensitizer (Ru) modified-TiO2 nanoparticles (NPs) loaded with siRNA of hypoxia-inducible factor-1α (HIF-1α). Under visible light irradiation, TiO2@Ru@siRNA can elicit both Type I and Type II photodynamic effects, which causes lysosomal damage, HIF-1α gene silencing, and O...
Source: Biomaterials - September 4, 2022 Category: Materials Science Authors: Jia-Ying Zhou Wen-Jin Wang Chen-Yu Zhang Yu-Yi Ling Xiao-Jing Hong Qiao Su Wu-Guo Li Zong-Wan Mao Bin Cheng Cai-Ping Tan Tong Wu Source Type: research

Immunogenomic-Based Analysis of Hierarchical Clustering of Diffuse Large Cell Lymphoma
J Immunol Res. 2022 Aug 9;2022:9544827. doi: 10.1155/2022/9544827. eCollection 2022.ABSTRACTDiffuse large B cell lymphoma (DLBCL) is one of the most usual types of adult lymphoma with heterogeneousness in histological morphology, prognosis, and clinical indications. Prior to this, several studies were carried out to determine the DLBCL subtype based on the analysis of the genome profile. However, classification based on assessment of genes related to the immune system has limited clinical significance for DLBCL. We systematically explored the DLBCL gene expression dataset and provided publicly available clinical informatio...
Source: Journal of Immunology Research - August 19, 2022 Category: Allergy & Immunology Authors: Longhao Wang Wei Yuan Lifeng Li Zhibo Shen Qishun Geng Yuanyuan Zheng Jie Zhao Source Type: research

Inhibition of SerpinB9 to enhance granzyme B-based tumor therapy by using a modified biomimetic nanoplatform with a cascade strategy
In this study, it was proved that SerpinB9 (Sb9) downregulation can enhance the GrB susceptibility of tumor cells. Moreover, a nanocarrier fused with M1 macrophage exosomes (M1 Exo) and photothermal sensitive liposomes was constructed to efficiently transport GrB and siRNA of Sb9 to the cells. The nanocarrier is characterized by cascade tumor targeting acquired by photothermal effect-triggered increased expression of vascular cell adhesion molecule-1 (VCAM-1) in tumor tissue. Furthermore, the innate cytokines in M1 Exo are capable of regulating the tumor microenvironment by repolarizing M2 macrophages to the M1 type. Colle...
Source: Biomaterials - August 13, 2022 Category: Materials Science Authors: Ran Han Luting Yu Chenxuan Zhao Ying Li Yuying Ma Yuewen Zhai Zhiyu Qian Yueqing Gu Siwen Li Source Type: research

Bioinformatics analysis and experimental verification of the prognostic and biological significance mediated by fatty acid metabolism related genes for hepatocellular carcinoma
ConclusionOur study identified a novel FA metabolism-related prognostic model, revealing a better potential treatment and prevention strategy for HCC.
Source: Frontiers in Oncology - August 2, 2022 Category: Cancer & Oncology Source Type: research

CTLA-4 silencing in dendritic cells loaded with colorectal cancer cell lysate improves autologous T cell responses in vitro
In this study, we loaded colorectal cancer (CRC) cell lysate on DCs and inhibited the expression of CTLA-4 by small interfering RNA (siRNA) in them to investigate the DCs’ functional and phenotypical features, and T-cell mediated responses following DC/T cell co-culture. Our results demonstrated that blockade of CTLA-4 could promote stimulatory properties of DCs. In addition, CTLA-4 silenced CRC cell lysate-loaded DCs compared to the DCs without CTLA-4 silencing resulted in augmented T cell proliferation and cytokine production, i.e., IFN-γ and IL-4. Taken together, our findings suggest CTLA-4 silenced CRC cell lysate-l...
Source: Frontiers in Immunology - August 1, 2022 Category: Allergy & Immunology Source Type: research

An optimized ionizable cationic lipid for brain tumor-targeted siRNA delivery and glioblastoma immunotherapy
Biomaterials. 2022 Jun 22;287:121645. doi: 10.1016/j.biomaterials.2022.121645. Online ahead of print.ABSTRACTGlioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor with a high mortality rate. Immunotherapy has achieved promising clinical results in multiple cancers, but shows unsatisfactory outcome in GBM patients, and poor drug delivery across the blood-brain barrier (BBB) is believed to be one of the main limitations that hinder the therapeutic efficacy of drugs. Herein, a new cationic lipid nanoparticle (LNP) that can efficiently deliver siRNA across BBB and target mouse brain is prepared fo...
Source: Biomaterials - July 2, 2022 Category: Materials Science Authors: Shuhan Liu Ji Liu Haisong Li Kuirong Mao Haorui Wang Xiandi Meng Jialiang Wang Chenxi Wu Hongmei Chen Xin Wang Xiuxiu Cong Yue Hou Ye Wang Ming Wang Yong-Guang Yang Tianmeng Sun Source Type: research

Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model
CONCLUSION: These findings strongly suggest that TMC-DS-L NPs loaded with siRNA could act as a novel tool in inhibiting the expression of immune checkpoints in the tumor microenvironment. Also, combination therapy based on inhibition of PD-1 and LAG3 in combination with DC vaccine is an effective method in treating cancer that needs to be further studied.PMID:35715669 | DOI:10.1007/s11095-022-03297-9
Source: Cell Research - June 17, 2022 Category: Cytology Authors: Asal Barshidi Vahid Karpisheh Fatemeh Karimian Noukabadi Fariba Karoon Kiani Mohammad Mohammadi Negin Afsharimanesh Farbod Ebrahimi Seyed Hossein Kiaie Jamshid Gholizadeh Navashenaq Mohammad Hojjat-Farsangi Naime Majidi Zolbanin Ata Mahmoodpoor Hadi Hassa Source Type: research

Cancer combination therapies by silencing of CTLA ‐4, PD‐L1, and TIM3 in osteosarcoma
ConclusionOur findings suggest that triple blockade of CTLA-4, PD-L1, and TIM3 is an effective strategy for inhibiting tumor cell progression and migration in OS, which requires large-scale clinical investigations to be translated into broad therapeutic applicability for OS patients.
Source: IUBMB Life - May 31, 2022 Category: Research Authors: Amin Daei Sorkhabi, Aila Sarkesh, Ali Fotouhi, Hossein Saeedi, Leili Aghebati ‐Maleki Tags: RESEARCH COMMUNICATION Source Type: research

Non-viral siRNA delivery to T cells: Challenges and opportunities in cancer immunotherapy
Biomaterials. 2022 Apr 5;286:121510. doi: 10.1016/j.biomaterials.2022.121510. Online ahead of print.ABSTRACTT lymphocytes are the major drivers of antitumor immunity. The recent clinical success of adoptive T cell therapies and immune checkpoint inhibitors has demonstrated the strength of modulating T cell function in fighting cancer. Nonetheless, a significant fraction of patients remain unresponsive largely due to the immunosuppressive tumor environment that blunts T cell activity. Small interfering RNAs (siRNAs) offer the potential to sequence-specifically silence the expression of negative regulator genes in T cells in...
Source: Biomaterials - May 24, 2022 Category: Materials Science Authors: Jelter Van Hoeck Kevin Braeckmans Stefaan C De Smedt Koen Raemdonck Source Type: research